21 février 2024
info:eu-repo/semantics/openAccess
adelage, « USA FDA Public consultation on Draft guidance (Catapult's regulatory round-up - June) », ELSIBI, ID : 10.58079/vvnd
Title Consultation period Category 1. Pediatric Drug Development: Regulatory Considerations — Complying With the Pediatric Research Equity Act and Qualifying for Pediatric Exclusivity Unde r the Best Pharmaceuticals for Children Act Guidance for Industry End date: 17 July 2023 Draft guidance Published on the 3rd of July 2023. Read the Regulatory Round-up – June 2023 (catapult.org.uk) following this link.